Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Non-Current Assets (2019 - 2025)

Cyclerion Therapeutics (CYCN) has disclosed Non-Current Assets for 7 consecutive years, with $5.4 million as the latest value for Q3 2025.

  • For Q3 2025, Non-Current Assets changed 0.0% year-over-year to $5.4 million; the TTM value through Sep 2025 reached $21.4 million, changed 0.0%, while the annual FY2024 figure was $5.4 million, 0.0% changed from the prior year.
  • Non-Current Assets hit $5.4 million in Q3 2025 for Cyclerion Therapeutics, roughly flat from $5.4 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $55.5 million in Q1 2021 and bottomed at $2.7 million in Q2 2021.
  • Average Non-Current Assets over 5 years is $7.1 million, with a median of $5.4 million recorded in 2023.
  • Year-over-year, Non-Current Assets tumbled 95.99% in 2021 and then soared 79.29% in 2024.
  • Cyclerion Therapeutics' Non-Current Assets stood at $3.9 million in 2021, then dropped by 15.88% to $3.3 million in 2022, then soared by 64.16% to $5.4 million in 2023, then changed by 0.0% to $5.4 million in 2024, then changed by 0.0% to $5.4 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $5.4 million, $5.4 million, and $5.4 million for Q3 2025, Q2 2025, and Q1 2025 respectively.